{"nctId":"NCT02986139","briefTitle":"Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis","startDateStruct":{"date":"2016-11-29","type":"ACTUAL"},"conditions":["Arthritis, Rheumatoid; Arthritis, Psoriatic"],"count":111,"armGroups":[{"label":"Sequence AB","type":"EXPERIMENTAL","interventionNames":["Drug: Commercial Formulation Etanercept","Drug: New Formulation Etanercept"]},{"label":"Sequence BA","type":"EXPERIMENTAL","interventionNames":["Drug: Commercial Formulation Etanercept","Drug: New Formulation Etanercept"]}],"interventions":[{"name":"Commercial Formulation Etanercept","otherNames":["Enbrel"]},{"name":"New Formulation Etanercept","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n* Subject has provided informed consent prior to initiation of any study specific activities/procedures.\n* Male or female subject is 18 years of age or older at time of signing the informed consent form.\n* Subject has a diagnosis of RA or PsA and indicated for treatment with etanercept per the current label, based on investigator judgment.\n* Subject is naïve to etanercept.\n* Subject is able to self-inject etanercept.\n\nExclusion Criteria\n\n* Subject is diagnosed with Felty's syndrome.\n* Subject has active erythrodermic, pustular, guttate psoriasis, or medication induced psoriasis, or other skin conditions.\n* Subject has a history of clinically significant skin allergies\n* Subject has a history of alcoholic hepatitis, nonalcoholic steatohepatitis or immunodeficiency syndromes.\n* Subject has any active infection for which anti-infectives were indicated within 4 weeks prior to screening.\n* Subject has had a serious infection, defined as requiring hospitalization or intravenous anti-infectives within 8 weeks prior to first dose of investigational product.\n* Subject had prosthetic joint infection within 5 years of screening or native joint infection within 1 year of screening.\n* Subject has known alcohol addiction or dependency.\n* Subject has positive hepatitis B surface antigen, hepatitis B core antibody (confirmed by hepatitis B virus deoxyribonucleic acid (DNA) test) or hepatitis C virus antibody serology at screening, or a positive medical history for hepatitis B or C. (Subjects with a history of hepatitis B vaccination without history of hepatitis B are allowed to enroll).\n* Subject has any active malignancy, including evidence of cutaneous basal or squamous cell carcinoma or melanoma.\n* Subject has known history of active tuberculosis.\n* Subject has used biologic disease modifying agent (DMARD) less than or equal to 3 months prior to screening.\n* If subject is receiving continuous treatment with acetaminophen, non-steroidal anti-inflammatory drug or tramadol, hydrocodone, oxycodone, codeine, and/or propoxyphene and the dose is within 4 hours before study visit and dose is not stable for ≥ 2 weeks before first dose of investigational product\n* For subjects not on continuous analgesics, subject has taken the following within 4 hours before screening: acetaminophen, non-steroidal anti-inflammatory drugs, hydrocodone, codeine, tramadol, propoxyphene, and/or oxycodone (unless in the form of OxyContin). For subjects not on continuous analgesics, subject has taken OxyContin within 24 hours before screening.\n* Subject has received live vaccines less than or equal to 4 weeks prior to first dose of investigational product.\n* Subject has laboratory abnormalities during screening.\n* Estimated creatinine clearance less than 50 mL/min.\n* Subject has any other laboratory abnormality, which, in the opinion of the investigator poses a safety risk, will prevent the subject from completing the study, or will interfere with the interpretation of the study results.\n* Subject is currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(s).\n* Other investigational procedures while participating in this study.\n* Women who are pregnant or breastfeeding, or planning to become pregnant or breastfeed during treatment and/or within 4 weeks after the last dose of etanercept.\n* Women of child-bearing potential with a positive pregnancy test.\n* Women of child-bearing potential who are unwilling to practice true sexual abstinence or unwilling to use 1 of the following effective birth control methods during treatment and for an additional 4 weeks after the last dose of etanercept.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Injection Site Pain","description":"Injection site pain was assessed using a 100 mm visual analog scale (VAS), from 0 mm (No Pain At All) to 100 mm (Worst Pain Imaginable). Participants were asked to indicate the severity of their pain at the injection site by placing a vertical line on the scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.6","spread":"22.3"},{"groupId":"OG001","value":"19.8","spread":"22.5"}]}]}]},{"type":"SECONDARY","title":"Injection Site Pain by Disease Indication","description":"Injection site pain was assessed using a 100 mm visual analog scale (VAS), from 0 mm (No Pain At All) to 100 mm (Worst Pain Imaginable). Participants were asked to indicate the severity of their pain at the injection site by placing a vertical line on the scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.7","spread":"20.2"},{"groupId":"OG001","value":"23.3","spread":"29.0"},{"groupId":"OG002","value":"20.5","spread":"22.6"},{"groupId":"OG003","value":"17.2","spread":"22.3"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events","description":"The severity of each adverse event was graded by the investigator using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":106},"commonTop":["Injection site reaction","Pain in extremity","Hypoaesthesia","Injection site erythema","Rash"]}}}